| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6185258 | Gynecologic Oncology | 2013 | 6 Pages |
Abstract
Our clinical outcome and safety data suggested that phase 1 trials may be a reasonable option for patients with advanced and recurrent gynecologic cancer. The potential prognosticators identified should be further validated in larger trials.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
June Y. Hou, Santiago Aparo, Mohammad Ghalib, Imran Chaudhary, Umang Shah, Umang Swami, Mark Einstein, Gary L. Goldberg, Sridhar Mani, Sanjay Goel,